Core Viewpoint - The company announced that its subsidiary, Stone Pharma, has achieved positive topline results in a Phase III clinical trial for its biosimilar drug, Secukinumab injection, aimed at treating moderate to severe plaque psoriasis [1][2] Group 1: Product Development and Clinical Trials - The product, Secukinumab injection, is a fully human IgG1 monoclonal antibody that specifically binds to IL-17A, a key molecule in the pathogenesis of psoriasis [1] - The Phase III clinical trial was a multicenter, randomized, double-blind, parallel, positive-controlled equivalence study designed to verify the consistency of efficacy between the product and Cosentyx in treating moderate to severe plaque psoriasis patients [2] - The primary endpoint of the study was the proportion of patients achieving a 75% improvement in the Psoriasis Area and Severity Index (PASI-75) score from baseline at week 12, which the study successfully met [2] Group 2: Market Context and Patient Impact - There are over 7 million psoriasis patients in China, highlighting a significant market opportunity for effective treatments [1] - The safety profile of the product was found to be good, with no new or unexpected safety signals, indicating it may meet the long-term safety needs of patients [2] - The detailed data from the study will be published in upcoming academic conferences and journals, which may further validate the product's efficacy and safety [2]

該產品是本集團開發的全人源Ig G1單克隆抗體藥物，為司庫奇尤單抗注射液（ 可善挺® ）的 生物類似藥。可善挺®在中國獲批的適應症包括6歲及以上斑塊狀銀屑病、銀屑病關節炎、 強直性脊柱炎及化膿性汗腺炎，其療效與安全性已獲得廣泛認可。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 司庫奇尤單抗注射液III期臨床試驗獲得頂線分析數據 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布 ， 本 公 司 附 屬 公 司 石 藥 集 團 巨 石 生 物 製 藥 有 限 公 司 開 發 的 司 庫 奇 尤 單 抗 注 射 液（「 該 產 品」）在用於治療中度至重度斑塊狀銀屑病的等效性III期臨床試驗中獲得頂線分析數據。 銀 屑 病 是 一 種 免 疫 相 關 的 慢 性 、 炎 症 性 、 系 統 性 疾 病 。 目 前 ， 中 國 約 有 超 700 萬 銀 屑 病 患 者。全人源白介素(IL) -1 ...

Group 1 - New Horizon (300765.SZ) announced that its subsidiary, Giant Stone Biopharmaceutical Co., Ltd., has obtained topline analysis data from the Phase III clinical trial of its drug, Secukinumab injection, which is a fully human IgG1 monoclonal antibody and a biosimilar to Cosentyx® [1][2] - Secukinumab is approved in China for indications including plaque psoriasis for patients aged 6 and above, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa, with its efficacy and safety widely recognized [1] - Psoriasis is a chronic, inflammatory, systemic disease related to the immune system, with approximately 7 million patients in China. The drug specifically binds to IL-17A, a key molecule in the pathogenesis of psoriasis, blocking IL-17 receptor signaling to suppress inflammation [1] Group 2 - The development of Secukinumab follows the research guidelines for biosimilars, and a head-to-head equivalence study was conducted against Cosentyx® [2] - This study is a multicenter, randomized, double-blind, parallel, positive-controlled Phase III clinical trial aimed at verifying the consistency of efficacy between Secukinumab and Cosentyx® in treating moderate to severe plaque psoriasis patients [2] - The primary endpoint was the proportion of patients achieving a 75% improvement in the Psoriasis Area and Severity Index (PASI-75) score from baseline by week 12. The study met its primary endpoint, demonstrating clinical equivalence and good safety profile without new or unexpected safety signals, indicating potential for long-term safety in patients [2]

Core Viewpoint - New Horizon (300765.SZ) announced that its subsidiary, Giant Biopharmaceutical Co., Ltd., has achieved positive topline results in the Phase III clinical trial of its drug, Tislelizumab injection, demonstrating clinical equivalence to the reference drug, Cosentyx [1] Group 1: Product Development - The drug Tislelizumab is a fully human IgG1 monoclonal antibody and a biosimilar to Cosentyx [1] - Cosentyx has been approved in China for indications including plaque psoriasis in patients aged 6 and above, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa [1] Group 2: Clinical Trial Results - The key study met its predefined primary endpoint and showed positive topline results [1] - Statistical analysis indicates that Tislelizumab has clinical equivalence to Cosentyx, with good safety profiles and no new or unexpected safety signals [1] - The drug is expected to meet the long-term safety needs of patients [1]

Core Viewpoint - The announcement from XinNuoWei (300765.SZ) indicates that its subsidiary, Giant Biopharmaceutical Co., Ltd., has achieved positive topline results in a Phase III clinical trial for its drug, a biosimilar to Cosentyx, which is expected to meet long-term safety requirements for patients [1] Group 1: Product Development - The drug developed by Giant Biopharmaceutical is a fully human IgG1 monoclonal antibody injection [1] - The biosimilar is designed to treat conditions including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa, which have been widely recognized for their efficacy and safety [1] Group 2: Clinical Trial Results - The key study has met its predefined primary endpoint, demonstrating clinical equivalence to Cosentyx [1] - Safety analysis showed no new or unexpected safety signals, indicating a favorable safety profile for the drug [1] - Detailed data from the trial will be presented at upcoming academic conferences and in journals [1]

Core Viewpoint - The announcement from XinNuoWei indicates that its subsidiary, Jushi Biopharma, has achieved top-line analysis data from the Phase III clinical trial of its drug, Secukinumab injection, which is a fully human IgG1 monoclonal antibody and a biosimilar to Cosentyx [1] Group 1: Product Development - Secukinumab is developed as a biosimilar to Cosentyx, which has been approved in China for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa [1] - The efficacy and safety of Cosentyx have been widely recognized in the medical community [1] Group 2: Market Context - Psoriasis is a chronic, inflammatory, systemic disease related to the immune system, with approximately 7 million patients suffering from psoriasis in China [1] - Interleukin (IL)-17A, primarily produced by activated T cells, is a key molecule in the pathogenesis of psoriasis [1] Group 3: Mechanism of Action - Secukinumab specifically binds to IL-17A, blocking the signaling of the IL-17 receptor, thereby inhibiting the inflammation associated with psoriasis [1]

Summary of Alvotech Conference Call Company Overview - Alvotech is a biosimilar company founded in 2013, aiming to become a leading player in the global biosimilar market with a focus on R&D, manufacturing, and marketing reach [2][3] - The company has invested approximately $2 billion since its inception and has around 30 products in its development pipeline [2][3] Industry and Market Position - Alvotech has launched five products outside the U.S. and plans to launch its first commercial product in the U.S. market in 2024 [3] - The company has experienced a compound annual growth rate (CAGR) of 74% from 2021 to 2026 [3] - Alvotech has established partnerships with 19 commercial partners, which contribute to R&D funding through milestone payments [4] Financial Performance - For the first nine months of 2025, Alvotech reported a revenue growth of 24%, with a gross margin of 59% [18][19] - EBITDA for the same period was at 16%, impacted by higher R&D and G&A costs [19] - The company has provided guidance for 2025, projecting revenues between $570 million and $600 million, and EBITDA between $130 million and $150 million, indicating a 19% year-on-year revenue increase and a 30% improvement in EBITDA [21][22] - For 2026, Alvotech anticipates revenues of $650 million to $700 million and adjusted EBITDA of $180 million to $220 million [22] Product Pipeline and Approvals - Alvotech has received complete response letters (CRLs) for three of its four Biologics License Applications (BLAs) submitted in Q4 2024, including biosimilars to Simponi and Eylea [9][10] - The company is optimistic about resolving outstanding issues with the FDA and is focused on scaling up and launching recently approved products in Europe and Japan [10][11] - The total addressable market for recently approved products outside the U.S. is approximately $3 billion [12] Regulatory and Compliance - Alvotech has undergone multiple inspections by regulatory authorities, including the FDA, EMA, and PMDA, with minor observations noted [6][31] - The company has implemented close to 200 corrective and preventive actions (CAPAs) to address FDA concerns and is working towards resolving issues related to product quality complaints and environmental monitoring [7][30][31] Strategic Focus - Alvotech's strategic focus for the next 18 months includes advancing its pipeline, supporting global product launches, and diversifying revenue across geographies and products [23] - The company plans to invest around $250 million in R&D for 2026 to maintain a strong biosimilar pipeline [23] Conclusion - Alvotech is positioned for significant growth in the biosimilar market, with a robust pipeline, strong partnerships, and a clear strategic focus on execution and market expansion [23][35]

Core Viewpoint - Fuhong Hanlin (复宏汉霖) is positioned as a leading player in the biosimilar drug market in China, focusing on hematological malignancies, solid tumors, and autoimmune diseases, with a strong emphasis on international collaboration and product commercialization [1][2] Group 1: Business Performance - In 2023, the company achieved profitability with projected revenue of 5.724 billion yuan in 2024, representing a 6% year-on-year growth, and a net profit of 815 million yuan, reflecting a 50% increase compared to the previous year [2] - The company is expected to enter a high-growth phase in overseas business by 2025, with overseas product profits projected to grow over 200% in the first half of 2025 [2] Group 2: Product Pipeline and R&D - HLX43, a potential BICPD-L1ADC, is under clinical development for multiple indications including lung cancer and gastric cancer, showing significant efficacy in clinical trials with an overall response rate (ORR) of 33.3% for squamous NSCLC and 48.6% for non-squamous NSCLC [3] - HLX22, in combination with trastuzumab, has shown improved efficacy and safety in treating HER2-positive gastric/gastroesophageal junction cancer, with ongoing global Phase III trials [3] - The company is also advancing the development of Surulitinib, which aims to replace postoperative chemotherapy in gastric cancer with immunotherapy, having met primary clinical endpoints [3] Group 3: Market Strategy and Valuation - The company has established a global presence with its biosimilar products, which are key drivers of revenue growth, and is considering implementing full circulation of H-shares to enhance liquidity [4] - The projected net profits for 2025-2027 are estimated at 823 million, 744 million, and 1.129 billion yuan respectively, with corresponding price-to-earnings ratios of 39, 43, and 28, suggesting a total market valuation between 52.1 billion and 67.9 billion yuan [4]

Core Viewpoint - Hualan Biological (002007.SZ) announced that its subsidiary, Hualan Gene Engineering Co., Ltd., received a notice of acceptance for the production registration application of Dexamethasone Injection from the National Medical Products Administration, marking a significant step towards market entry for this biosimilar drug [1][2] Group 1 - The Dexamethasone Injection developed by the company is a biosimilar, with the original product developed by Amgen and approved in multiple countries for treating various bone diseases, including osteoporosis and giant cell tumors [1] - Dexamethasone is a humanized monoclonal antibody (IgG2 type) that targets RANKL, a key factor necessary for osteoclast formation and function, thereby preventing bone-related events caused by malignant tumor bone metastasis [1] - The drug effectively inhibits osteoclast-mediated bone resorption and destruction, making it an important supportive treatment for cancer patients [1] Group 2 - Currently, four companies in China have received approval for Dexamethasone Injection, including Jiangsu Taikang Biopharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd., Shandong Boan Biotechnology Co., Ltd., and Canaan Jereh (Jilin) Biotechnology Co., Ltd. [2] - If Hualan Gene receives approval, it will enhance the product portfolio of the company and provide a new profit growth point [2]

Core Viewpoint - The company announced that its affiliate, Hualan Gene Engineering Co., Ltd., received a notice of acceptance for the production registration application of denosumab injection from the National Medical Products Administration, marking a significant step towards market entry for this biosimilar drug [1]. Group 1: Product Development - The denosumab injection developed by the company is a biosimilar drug, with the original product developed by Amgen and approved in multiple countries for treating various bone diseases, including osteoporosis and giant cell tumors [1]. - Denosumab is a humanized monoclonal antibody (IgG2 type) that specifically targets RANKL, a key factor necessary for the formation, function, and survival of osteoclasts [1]. Group 2: Market Context - Currently, four companies in China have received approval for denosumab injection, including Jiangsu Taikang Biopharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd., Shandong Boan Biotechnology Co., Ltd., and Cangzhou Jereh Biotech Co., Ltd. [2]. - If Hualan Gene Engineering Co., Ltd. receives approval, it will enhance the product portfolio of the company and provide a new profit growth point [2].